BREAST

CALGB 40502

A Randomized Phase III Trial of Weekly Paclitaxel Compared to Weekly Nanoparticle Albumin Bound (NAB) – Paclitaxel or Ixabepitilone Combined with Bevacizumab as First of Second-Line Therapy for Locally Recurrent or Metastatic Breast Cancer

CALGB 70305

A Randomized Study to Prevent Lymphedema in Women Treated for Breast Cancer

ECOG E5103

A Double-Blind Phase III Trial of Dose Dense Doxorubicin and Cyclophosphamide Followed by Paclitaxel with Bevacizumab or Placebo in Patients with Lymph Node Positive and High Risk Lymph Node Negative Breast Cancer

NSABP 43

A Phase III Clinical Trial Comparing Trastuzumab Given Concurrently with Radiation Therapy and Radiation Therapy Alone for Women with HER2-Positive Ductal Carcinoma in Situ Resected by Lumpectomy

PACCT-1/TAILOR

Program for the Assessment of Clinical Cancer Tests (PACCT-1): Trial Assigning Individualized Options for Treatment: The TAILORx Trial

COLON/COLORECTAL

ECOG E5202

A Randomized Phase III Study Comparing 5-FU, Leucovorin and Oxaliplatin versus 5-FU, Leucovorin, Oxaliplatin and Bevacizumab in Patients with Stage II Colon Cancer at High Risk for Recurrence to Determine Prospectively the Prognostic Value of Molecular Markers

SWOG S0600

Phase III Trial of Irinotecan-Based Chemotherapy Plus Cetuximab (NSC-714692) with or without Bevacizumab (NSC-704865) as Second-Line Therapy for Patients with Metastatic Colorectal Cancer who have Progressed on Bevacizumab with either FOLFOX, OPTIMOX or XELOX

MDS

ECOG E2905

Randomized Phase III Trial Comparing the Frequency of Major Erythroid Response (MER) to Treatment with Lenalidomide (Revlimid®) Alone and in Combination with Epoetin Alfa (Procrit®) in Subjects with Low- or Intermediate-1 Risk MDS and Symptomatic Anemia

NON-SMALL CELL LUNG CANCER

CALGB 30607

Randomized, Phase III, Double-Blind Placebo-Controlled Trial of Sunitinib (NSC #736511, IND #74019) as Maintenance Therapy in Non-Progressing Patients following an Initial Four Cycles of Platinum-Based Combination Chemotherapy in Advanced, Stage IIIB/IV Non-Small Cell Lung Cancer

FER-TH-007

Phase II Study of Bevacizumab and Erlotinib in Elderly Patients with Advanced Non-Small Cell Lung Cancer

ECOG E1505

A Phase III Randomized Trial of Adjuvant Chemotherapy with or without Bevacizmub for Patients with Completely Resected State IB (> 4cm) – IIIA Non-Small Cell Lung Cancer (NSCLC)

RTOG 0617

A Randomized Phase III Comparison of Standard-Dose (60 Gy) versus High-Dose (74 Gy) Conformal Radiotherapy with Concurrent and Consolidation Carboplatin/Paclitaxel +/- Cetuximab (IND #103444) in Patients with Stage IIIa/IIIb Non-Small Cell Cancer

MDS

ECOG E2905

Randomized Phase III Trial Comparing the Frequency of Major Erythroid Response (MER) to Treatment with Lenalidomide (Revlimid®) Alone and in Combination with Epoetin Alfa (Procrit®) in Subjects with Low- or Intermediate-1 Risk MDS and Symptomatic Anemia

QUALITY OF LIFE/SURVIVORSHIP STUDIES

FER-001

Measuring Quality Improvement in Breast Cancer Care and Management Throughout Fox Chase Cancer Center Partners’ Hospital

FER-002

Life After Cancer: Examining Survivor Transitions from Specialist to Primary Care

NSABP BP-59

Bone Marrow Analysis in Early-Stage Breast Cancer

Yoga/ARMC/RSC

Impact of Yoga and Meditation on Aromatase Inhibitor Musculoskeletal Symptoms (AIMSS) for Breast Cancer: A Pilot Study

For more information about clinical trials at AtlantiCare, please contact the Oncology Research Coordinator, Office of Oncology Research at 609-677-7735.

Back to Top